Nabriva Therapeutics PLC (STU:NTY)
€ 1.25 0.02 (1.63%) Market Cap: 2.76 Mil Enterprise Value: 1.62 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 39/100

Nabriva Therapeutics plc - Special Call Transcript

Aug 19, 2019 / 08:30PM GMT
Release Date Price: €462.5 (-6.57%)
Operator

Good afternoon, ladies and gentlemen, and welcome to the Nabriva Therapeutics Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the call over to David Garrett, Vice President, Corporate Controller and Head of Investor Relations. You may begin.

David Garrett
Nabriva Therapeutics GmbH - Head of IR, VP & Corporate Controller

Thank you, and good afternoon, everyone. Welcome to Nabriva's Conference Call and Webcast to discuss the FDA approval of XENLETA. Press release summarizing the approval labeling indications, was issued today at 3:30 Eastern Time, can be found at www.nabriva.com. An accompanying slide presentation is also being -- is also available on the Events and Presentation page in the Investors section of our website. We invite you to take a moment to open the file and follow the presentation along with us.

Before we begin, I would like to remind everyone that this conference call and webcast will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot